News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lev Pharmaceuticals, Inc. to Submit Cinryze™ Application to the European Medicines Evaluation Agency



7/1/2008 10:56:30 AM

NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP) announced today that it has entered into a letter agreement with the Sanquin Blood Supply Foundation (“Sanquin”), authorizing Lev to file for European marketing authorization of its lead product candidate, Cinryze™ [C1 inhibitor (human)], for the treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES